The American Journal of Managed Care

Linking T-Cell Composition to CAR T Efficacy in Multiple Myeloma

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
The American Journal of Managed Care

Allogeneic vs Autologous CAR T-Cell Therapy Explained

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Medscape

In Vivo CAR T-Cell Therapy Shows Potential in Refractory SLE

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...
Medscape

New Syndrome With CAR T-Cell Therapy in Autoimmune Diseases

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
Cure Today

First Patient with CD5-Positive T-Cell Lymphoma Dosed with MB-105

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...